63170-77-4

Basic information

• Product Name: 2(1H)-Pyrimidinone, 4-methyl-, hydrazone (9CI)
• Synonyms: 2(1H)-Pyrimidinone, 4-methyl-, hydrazone (9CI);2-hydrazinyl-4-methylPyrimidine;2-Hydrazinyl-4-methylpyrimidine hydrochloride
• CAS NO: 63170-77-4
• Molecular Formula: C₅H₈N₄
• Molecular Weight: 124.14382
• Product Categories: PYRIMIDINE
• Mol File: 63170-77-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Pyrimidinone, 4-methyl-, hydrazone (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyrimidinone, 4-methyl-, hydrazone (9CI)(63170-77-4)
• EPA Substance Registry System: 2(1H)-Pyrimidinone, 4-methyl-, hydrazone (9CI)(63170-77-4)

Safety Data

• Hazardous Substances Data: 63170-77-4(Hazardous Substances Data)

Usage

Potential applications

pharmaceuticals, agrochemicals, and materials science research

Role

versatile building block in the synthesis of various organic compounds

Biological activities

potential target for drug discovery and development

Specific uses and characteristics

depend on interactions with other substances and mechanism of action

Further study and research

necessary to fully understand potential applications and effects.

Upstream product

• 13036-57-2 2-chloro-4-methylpyrimidine 
• 14001-63-9 2-methylthio-4-methylpyrimidine 

Downstream Products

• 92723-79-0 benzaldehyde-(4-methyl-pyrimidin-2-ylhydrazone) 
• 3438-46-8 4-Methylpyrimidine 
• 15231-48-8 4-methyl-1H-pyrimidin-2-one 
• 205443-47-6 2,6-Di-tert-butyl-4-[(4-methyl-pyrimidin-2-yl)-hydrazonomethyl]-phenol 

Relevant articles and documents

Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis

Herein we report the discovery of a series of new KDM5A inhibitors. A three-dimensional (3D) structure model of KDM5A jumonji domain was firstly established based on homology modeling. Molecular docking-based virtual screening was then performed against c

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).